ArticleProceedings of the National Academy of Sciences of the United States of America1994
Synergistic binding of the Vibrio fischeri LuxR transcriptional activator domain and RNA polymerase to the lux promoter region.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 239 citations in OpenAlex.
- Expanding the LuxR-type receptor functional repertoire: Protein-protein interactions in quorum sensing regulation.PLoS pathogens · 2026Review
- Anti-quorum, anti biofilm activity of FDA approved drugs against P. aeruginosa: in silico and in vitro studies.Biotechnology letters · 2026Article
- Challenges and Opportunities: Interplay between Infectious Disease and Antimicrobial Resistance in Medical Device Surface Applications.ACS omega · 2025Review
- The Balance between Protealysin and Its Substrate, the Outer Membrane Protein OmpX, RegulatesInternational journal of molecular sciences · 2024Review
- Investigating Sulforaphane's anti-virulence and anti-quorum sensing properties againstFrontiers in pharmacology · 2024Article
- Quorum sensing facilitates interpopulation signaling byIsrael journal of chemistry · 2023Article
- Synergistic Benefits: Exploring the Anti-Virulence Effects of Metformin/Vildagliptin Antidiabetic Combination againstBiomedicines · 2023Article
- RETRACTED: Characterization of the Anti-Biofilm and Anti-Quorum Sensing Activities of the β-Adrenoreceptor Antagonist Atenolol against Gram-Negative Bacterial Pathogens.International journal of molecular sciences · 2022Article
- Application of quorum sensing system in microbial synthesis of valuable chemicals: a mini-review.World journal of microbiology & biotechnology · 2022Review
- Redesigning regulatory components of quorum-sensing system for diverse metabolic control.Nature communications · 2022Article
- Terazosin Interferes with Quorum Sensing and Type Three Secretion System and Diminishes the Bacterial Espionage to Mitigate theAntibiotics (Basel, Switzerland) · 2022Article
- RepurposingAntibiotics (Basel, Switzerland) · 2022Article
- Computational and Biological Evaluation ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Gossip in the gut: Quorum sensing, a new player in the host-microbiota interactions.World journal of gastroenterology · 2021Review
- The Role of SprIR Quorum Sensing System in the Regulation ofMicroorganisms · 2021Article
- Microbial biofilm ecology, in silico study of quorum sensing receptor-ligand interactions and biofilm mediated bioremediation.Archives of microbiology · 2021Review
- Article
- Screening of Bacterial Quorum Sensing Inhibitors in aPharmaceuticals (Basel, Switzerland) · 2020Article
- Regulatory Mechanisms and Promising Applications of Quorum Sensing-Inhibiting Agents in Control of Bacterial Biofilm Formation.Frontiers in microbiology · 2020Review
- Functional characterization of quorum sensing LuxR-type transcriptional regulator, EasR inPeerJ · 2020Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
LuxR, the Vibrio fischeri luminescence gene (lux) activator, is the best-studied member of a family of bacterial transcription factors required for cell density-dependent expression of specific genes involved in associations with eukaryotic hosts. Neither LuxR nor any other LuxR homolog has been shown to bind DNA directly. We have purified the LuxR C-terminal transcriptional activator domain from extracts of recombinant Escherichia coli in which this polypeptide was expressed. The purified polypeptide by itself binds to lux regulatory DNA upstream of the lux box, a 20-bp palindrome that is required for LuxR activity in vivo, but it does not bind to the lux box. However, the LuxR C-terminal domain together with RNA polymerase protects a region including the lux box and the lux operon promoter from DNase I cleavage. There is very little protection of the lux operon promoter region from DNase I digestion in the presence of RNA polymerase alone. Apparently, there is a synergistic binding of the LuxR C-terminal domain and RNA polymerase to the promoter region. The upstream binding region for the purified polypeptide encompasses a binding site for cAMP receptor protein (CRP). Under some conditions, CRP binding can block the binding of the LuxR C-terminal domain to the upstream binding region, and it can also block the synergistic binding of the LuxR C-terminal domain and RNA polymerase to the lux box and luminescence gene promoter region. This description of DNA binding by the LuxR C-terminal domain should lead to an understanding of the molecular interactions of the LuxR family of transcriptional activators with regulatory DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.